FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency
Pharmacy Times
JULY 7, 2025
Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.
Let's personalize your content